Clinical Trial Update: Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating GV1001 for efficacy and safety in benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• GV1001

Snippet

Sponsor: GemVax & Kael | Conditions: Benign Prostatic Hyperplasia (BPH) | Phase 3 | Status: COMPLETED